Business Wire

KY-ADTRAN

7.3.2024 14:31:27 CET | Business Wire | Press release

Share
South Central Rural Telecommunications Cooperative uses Adtran’s ALM to rapidly detect fiber faults

Adtran today announced that South Central Rural Telecommunications Cooperative (SCRTC) is using its ALM in-service fiber monitoring solution to continuously probe its fiber network for faults and degradations. The comprehensive assurance platform empowers SCRTC to locate and resolve issues before they impact services for its customers across South Central Kentucky. With no need to engage in time-consuming manual fault isolation, SCRTC can leverage its maintenance resources more effectively to improve service delivery for its subscribers. To enhance scalability, SCRTC has implemented Adtran’s ALM 96-port expansion unit at three of its hub sites. This enables efficient monitoring of up to 110 fiber links from a single hub location, significantly enhancing SCRTC’s capability to proactively detect and address faults.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307876673/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SCRTC is using Adtran’s fiber monitoring solution to reduce network downtime and cut operational costs. (Photo: Business Wire)

“The moment we plugged ALM into our infrastructure, it notified us of an issue affecting one of our protected routes. We’d been told to expect a quick return on our investment, but to get an immediate demonstration of what it could do for us was a surprise,” said Lonnie Meredith, network manager at SCRTC. “The ALM’s ability to detect, identify and locate fiber faults in real time has had a profound impact on our operations, minimizing network downtime and cutting operational costs. It only becomes clear just how essential the Adtran ALM is once it’s operational in your network. For our subscribers, it means receiving high-speed broadband with unbeatable reliability. And for us, it translates into daily operations that are more efficient and more cost-effective. It’s a tool you can’t afford to be without.”

SCRTC is using the 16-port variant of Adtran’s ALM to continuously monitor its core fiber network and high-traffic routes alongside the 96-port extender at three hub sites. A key component of SCRTC’s network management system is Adtran’s GIS-based tracking solution, Ensemble Fiber Director. This works with ALM to precisely track the location of issues and ensure optimized oversight of SCRTC’s full optical infrastructure. The system acts like a radar that continuously scans fiber optic cables to pinpoint the location of issues such as attenuation, water damage and breaks. By identifying problems early and enabling maintenance teams to immediately track them down, ALM also helps reduce SCRTC’s operational and capital expenditures. What’s more, its fanless operation and low power consumption further contribute to network efficiency and cost-effectiveness.

“When a service outage occurs, subscribers expect rapid resolution. That’s because broadband has become such an essential utility. Businesses, people working from home and families who regularly access entertainment streaming demand consistent, always-on connectivity. That’s why service providers like SCRTC are seeking solutions that take network resiliency to the next level,” commented John Scherzinger, GM of Americas sales at Adtran. “It’s often not until our customers experience the benefits of ALM’s proactive monitoring firsthand that they fully appreciate its critical role in operations. The SCRTC team is now well aware of the advantages it brings in minimizing efforts, bolstering network resilience and ensuring customer satisfaction.”

About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240307876673/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release

Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye